|
Volumn 22, Issue 10, 1998, Pages 601-604
|
Antipsychotic medication in learning disability: Impact of audit and evidence-based medicine on quality of prescribing in a community assessment treatment unit
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
BENZODIAZEPINE DERIVATIVE;
CARBAMAZEPINE;
CHLORPROMAZINE;
DIAZEPAM;
DROPERIDOL;
FLUOXETINE;
FLUPENTIXOL;
HALOPERIDOL;
LORAZEPAM;
METOCLOPRAMIDE;
MUSCARINIC RECEPTOR BLOCKING AGENT;
NEUROLEPTIC AGENT;
PAROXETINE;
RISPERIDONE;
SERTRALINE;
THIORIDAZINE;
VALPROIC ACID;
VENLAFAXINE;
ZUCLOPENTHIXOL;
AKATHISIA;
ARTICLE;
CLINICAL PRACTICE;
COMMUNITY MENTAL HEALTH CENTER;
DRUG USE;
EVIDENCE BASED MEDICINE;
HUMAN;
LEARNING DISORDER;
MEDICAL AUDIT;
MEDICAL DOCUMENTATION;
MENTAL PERFORMANCE;
ORAL DRUG ADMINISTRATION;
PRACTICE GUIDELINE;
PSYCHOPHARMACOLOGY;
RESOURCE MANAGEMENT;
RISK BENEFIT ANALYSIS;
TARDIVE DYSKINESIA;
TEAMWORK;
TOTAL QUALITY MANAGEMENT;
UNITED KINGDOM;
|
EID: 0031662090
PISSN: 09556036
EISSN: None
Source Type: Journal
DOI: 10.1192/pb.22.10.601 Document Type: Article |
Times cited : (3)
|
References (24)
|